There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company.
Investor's Business Daily on MSN
Eli Lilly stock hovers in buy zone, finds key support amid $3 billion deal
Sector leader Eli Lilly is in a buy zone above a pivot at 1,133.95 ahead of second-quarter results, due on Aug. 5.
I n 1876 Eli Lilly, a veteran of the civil war, founded a company in Indianapolis to bring scientific rigour to a medicines ...
Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.
Dave Ricks steered the 150-year-old drug giant to a $1 trillion market cap. Can he defeat pharma’s boom and bust cycle?
On the Jan. 5, 2026, episode of The Morning Filter podcast, Morningstar Chief US Market Strategist Dave Sekera commented on what the Food and Drug Administration’s approval of Novo Nordisk’s NVO ...
Viking's latest program seeks to push the envelope in weight loss efficacy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results